Insilico Medicine has licensed its AI-discovered oral PHD inhibitor ISM4808 to TaiGen Biotechnology for exclusive development and commercialization in the Greater China region, including Mainland China, Hong Kong, Macau, and Taiwan. The deal follows Investigational New Drug clearance in China in 2023 and positions TaiGen to bring the asset into clinical trials targeting anemia associated […]
Alphyn Biologics has secured $25 million in a twice-oversubscribed Series B financing round to support its clinical pipeline for dermatologic conditions. The funding will enable the company to advance a global Phase 2b trial of its lead asset, Zabalafin Hydrogel, for atopic dermatitis, while also launching a second Phase 2 program for molluscum contagiosum virus. […]
Swedish Orphan Biovitrum AB has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for Aspaveli, the pegcetacoplan-based therapy developed in partnership with Apellis Pharmaceuticals Inc., for the treatment of C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis. The recommendation covers use in patients aged 12 years and older […]
Ractigen Therapeutics has initiated human testing of RAG-18, a novel small activating RNA (saRNA) therapeutic candidate for Duchenne muscular dystrophy (DMD), by dosing the first patient in an investigator-initiated trial at Peking Union Medical College Hospital in Beijing. The study is being led by Professor Dai Yi, a recognized expert in neuromuscular disorders, and will […]
Actinium Pharmaceuticals, Inc. has presented new preclinical data for its alpha-particle radiotherapy candidate ATNM-400 at the 2025 San Antonio Breast Cancer Symposium (SABCS), highlighting potent anti-tumor activity across hormone receptor–positive, triple-negative, and therapy-resistant breast cancer models. The findings suggest that ATNM-400 could become a differentiated treatment option for patients with tumors that have progressed after […]
AusperBio Therapeutics, Inc. announced that its lead investigational product, AHB-137, achieved a 30% functional cure rate as a 24-week monotherapy in HBeAg-negative chronic hepatitis B patients already on stable nucleos(t)ide analogue therapy. The data, presented at HEP-DART 2025, showed that patients with baseline HBsAg 100–1,000 IU/mL reached this endpoint at Week 72 in the company’s […]
NanOlogy, LLC, a Texas-based clinical-stage oncology company, has announced the launch of a drug development program focused on diffuse intrinsic pontine glioma, known as DIPG, a universally fatal pediatric brainstem tumor. The company is advancing Large Surface Area Microparticle Cisplatin, or LSAM-cisplatin, designed for stereotactic intratumoral administration in children. Investigational New Drug–enabling studies are underway, […]
Eli Lilly and Company has released updated Phase 3 EMBER-3 results for Inluriyo, also known as imlunestrant, its oral estrogen receptor antagonist, in patients with estrogen receptor-positive and human epidermal growth factor receptor 2–negative advanced or metastatic breast cancer. These new data, presented at the 2025 San Antonio Breast Cancer Symposium and published in Annals […]
Johnson & Johnson (J&J) announced on December 12, 2025, that the U.S. Food and Drug Administration approved AKEEGA, a dual-action tablet combining niraparib and abiraterone acetate, alongside prednisone, for treating BRCA2-mutated metastatic castration-sensitive prostate cancer. The regulatory nod, based on the pivotal AMPLITUDE trial, makes AKEEGA the first precision medicine combination approved for this high-risk […]
Phare Bio and Basilea partner to develop an AI-designed antibiotic for deadly gram-negative infections. Explore what this deal could mean for the future of antimicrobial R&D.